Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration

Elisabeth R Wilson, Lisa Eidenschink Brodersen, PhD, Barbara Katharina Zehentner, PhD, Andrew J. Menssen, Andrew P. Voigt, Laura Pardo, Denise A. Wells, MD, Johann Hitzler, MD FRCP (C), FAAP, Jason N. Berman, MD, Todd A. Alonzo, PhD, Samir B. Kahwash, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2016) 128 (22): 1687.

https://doi.org/10.1182/blood.V128.22.1687.1687

Published: 2016

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

Journal Articles

Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

Karen R. Rabin, MD PhD, Johann Hitzler, MD FRCP (C), FAAP, Vilmarie Rodriguez, MD, Reuven Schore, MD, Anne Angiolillo, MD, Michael J. Burke, MD, Wanda Salzer, MD, Kelly Maloney, MD, Xiaomin Lu, PhD, Meenakshi Devidas, PhD, Mignon L. Loh, MD, Elizabeth Raetz, MD, Stephen P Hunger, MD

Blood (2015) 126 (23): 2502.

https://doi.org/10.1182/blood.V126.23.2502.2502

Published: 2015

Journal Articles

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

Oussama Abla, MD, Raul C. Ribeiro, MD, Anna Maria Testi, MD, Pau Montesinos Fernández, MD, Ursula Creutzig, MD, Lillian Sung, MD PhD, Giancarlo Di Giuseppe, BSc, Derek Stephens, MSc, Henrik Hasle, MD PhD, Gertjan J.L. Kaspers, MD PhD, Luciano Dalla-Pozza, MB BS FRACP, Alvaro Lassaletta, MD, Martin S. Tallman, MD, Franco Locatelli, MD, Dirk Reinhardt, MD, Johann Hitzler, MD FRCP (C), FAAP, Miguel A. Sanz, MD PhD

Blood (2015) 126 (23): 172.

https://doi.org/10.1182/blood.V126.23.172.172

Published: 2015

Journal Articles

Long-Term Results of a Low-Dose Cytarabine-Based Regimen for the Treatment of Acute Megakaryoblastic Leukemia and Myelodysplastic Syndrome in Children with Down Syndrome.

Johann Hitzler, MD, Ali Al-Ahmari, MD, Niketa Shah, MD, Lillian Sung, MD, PhD, Alvin Zipursky, MD

Blood (2005) 106 (11): 4987.

https://doi.org/10.1182/blood.V106.11.4987.4987

Published: 2005

Journal Articles

Secondary Cytogenetic Abnormalities and Outcome in Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia.

Oussama A. Abla, Johann Hitzler, Charles Ye, Mohamed Abdelhaleem, Ronald Grant, Gloria Nie, Shanthini Kangesan, Ikuko Teshima, Mary Shago

Blood (2005) 106 (11): 1450.

https://doi.org/10.1182/blood.V106.11.1450.1450

Published: 2005

NARROW

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

Long-Term Results of a Low-Dose Cytarabine-Based Regimen for the Treatment of Acute Megakaryoblastic Leukemia and Myelodysplastic Syndrome in Children with Down Syndrome.

Secondary Cytogenetic Abnormalities and Outcome in Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

Long-Term Results of a Low-Dose Cytarabine-Based Regimen for the Treatment of Acute Megakaryoblastic Leukemia and Myelodysplastic Syndrome in Children with Down Syndrome.

Secondary Cytogenetic Abnormalities and Outcome in Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only